An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Trial Status: active
This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in
participants with select advanced solid tumors known to express CEACAM5.
Inclusion Criteria
Documented histologically or cytologically confirmed, advanced, unresectable/metastatic solid tumor measurable by RECIST v1.1.
CRC: Part 1A, Part 2A-CRC, Part 1B, and Part 2B:. i) Locally advanced/metastatic, recurrent, or unresectable CRC with adenocarcinoma histology and whose disease has progressed after systemic cancer therapy in the metastatic or adjuvant setting including 5-FU, irinotecan, and/or oxaliplatin (if available and not contraindicated).
NSCLC: Part 2A-NSCLC/GC, 3L+ NSCLC:. i) Histologically confirmed NSCLC meeting stage criteria for Stage IIIB, Stage IV, or recurrent disease. ii) Progressed on at least 2 prior lines of therapy, iii) Participants must have received and progressed on or after anti-PD-(L)1 therapy, if
available.
GC: Part 2A-NSCLC/GC, 2L+ GC:. i) Participants must have received and then progressed or been intolerant to at least 1
standard treatment regimen in the advanced or metastatic setting (or have progressed
within 6 months of adjuvant therapy). ii) ECOG performance status of 0 or 1.
Exclusion Criteria
History of anaphylactic reactions to irinotecan and/or bevacizumab.
Previously received therapy targeting CEACAM5.
Grade ≥ 3 ILD/pneumonitis.
Other protocol-defined Inclusion/Exclusion criteria apply.
Additional locations may be listed on ClinicalTrials.gov for NCT06730750.
